with us
together we’re making a difference

News Releases

Dec 16, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2024 |

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 05, 2024 |

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

Nov 15, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Nov 14, 2024 |

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 13, 2024 |

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Oct 21, 2024 |

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 16, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2024 |

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Sep 16, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 38
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
investors@annexonbio.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2024 Annexon Inc. All rights reserved.